As shown in Figure 4C, PLOD2 was significantly correlated with 19 immune checkpoints in patients with STAD, of which 80% (14/19, CD200, CD276, CD28, CD44, CD80, CD86, HAVCR2, LAIR1, NRP1, PDCD1LG2, TNFRSF25, TNFRSF9, TNFSF14, TNFSF18, TNFSF4) was positively correlated. This evidence concerns the gene CD80 and gastric adenocarcinoma.